Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC : From Mechanisms to Translational Applications
Cancer Medicine · 2026-06 · 15 (6)
DOI: 10.1002/cam4.72061 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 23.06.2026. Verfasst von Liming Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine, Wuxi, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Gastrointestinal Microbiome, Immunotherapy, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 205 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Traditional Chinese Medicine Technology Development Plan of Jiangsu Provincial Administration of Traditional Chinese Medicine, Science and Technology Plan Project of Traditional Chinese Medicine Hospitals from Wuxi Municipal Administration of Traditional Chinese Medicine, Natural Science Foundation of Nanjing University of Chinese Medicine.
Abstract (Originalsprache)
The gut microbiome has emerged as a pivotal regulator of immunotherapy efficacy in non‐small cell lung cancer (NSCLC), with mounting evidence demonstrating that microbial‐immune crosstalk significantly influences therapeutic responses. Current research reveals that commensal bacteria modulate host immunity through complex metabolic and immunological pathways, yet the precise mechanisms underlying these interactions remain incompletely characterized. Meanwhile, the substantial heterogeneity of microbial ecosystems across individuals and the lack of standardized protocols for microbiota‐based therapeutic interventions pose significant barriers to clinical translation. Furthermore, unresolved questions persist regarding the safety profiles and reproducibility of clinical outcomes associated with microbial modulation. Addressing these knowledge gaps could provide transformative insights into immunotherapy resistance while enabling the development of precision medicine approaches. This narrative review synthesizes current knowledge on the clinical impact of gut microbiota on the immunotherapy response in NSCLC, mechanistic insights into the interactions between gut microbiota and the lung cancer immune microenvironment, and the challenges in clinical translation. By integrating these perspectives, we develop a practical framework for implementing microbiota‐based strategies to enhance immunotherapy efficacy, with the hope of addressing current limitations in biomarker development, intervention protocols, and personalized treatment approaches to bridge the gap between research and clinical practice in precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine, Wuxi, China.
ORCID-Profile: Dong Niu
Förderung
- Traditional Chinese Medicine Technology Development Plan of Jiangsu Provincial Administration of Traditional Chinese Medicine
- Science and Technology Plan Project of Traditional Chinese Medicine Hospitals from Wuxi Municipal Administration of Traditional Chinese Medicine
- Natural Science Foundation of Nanjing University of Chinese Medicine
Zitieren
APA
Zhu, L., Xu, J., Niu, D., Zhang, X., & Jin, C. (2026). Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC : From Mechanisms to Translational Applications. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.72061
Vancouver
Zhu L, Xu J, Niu D, Zhang X, Jin C. Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC : From Mechanisms to Translational Applications. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.72061
BibTeX
@article{Zhu2026,
author = {Zhu, Liming and Xu, Jiayao and Niu, Dong and Zhang, Xiangyu and Jin, Chunhui},
title = {Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC : From Mechanisms to Translational Applications},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cam4.72061}
}
EUVIMED